ASH Clinical News ACN_6.4s_SUPP_full_issue | Page 7

MARCH 2020 AMERICAN SOCIETY OF HEMATOLOGY HEADQUARTERS 2021 L Street NW, Suite 900 Washington, DC 20036 www.hematology.org Tel: [phone] CONTENTS EDITOR-IN-CHIEF David Steensma, MD Dana-Farber Cancer Institute Boston, MA ASSOCIATE EDITORS Elizabeth Brém, MD UC Irvine Medical Center Orange, CA Beth Faiman, CNP, PhD Cleveland Clinic Cleveland, OH Aristoteles Giagounidis, MD Marien Hospital Düsseldorf, Germany Alice Ma, MD University of North Carolina School of Medicine Chapel Hill, NC NEWLY APPROVED DRUGS IN THE LITERATURE Mayo Clinic Rochester, MN A review of the regulatory approvals for lymphoid and plasma cell malignancies from the last year 6 Adding Isatuximab to Dexamethasone- Pomalidomide Combination Improves PFS in Pretreated Myeloma 31 PUBLISHER American Medical Communications FEATURES Outcomes With Idelalisib Differ in the Clinical Trial Versus Real-World Setting 32 Joseph Mikhael, MD, MEd City of Hope Cancer Center Phoenix, AZ Alexandra Wolanskyj-Spinner, MD EDITORIAL MANAGING EDITORS Kristin Hubing, ASH Ariel Jones-DeMaio, AMC EDITORIAL COORDINATOR Sabrina Ahle, AMC ART DIRECTOR Ari Mihos ASSISTANT ART DIRECTORS Charlene DePrizio John Salesi DIGITAL PROJECTS MANAGER Chris Gedikli ADVERTISING ACCOUNT MANAGERS Nick Luciano [email protected] Kim Silverman [email protected] Phil Soufleris [email protected] Recruitment advertising orders can be sent to: DIRECTOR, RECRUITMENT CLASSIFIEDS Lauren Morgan [email protected] ©2020 by the American Society of Hematology. All materials contained in this newsletter are protected by copyright laws and may not be used, reproduced, or otherwise exploited in any manner without the express prior written permission of ASH Clinical News. Any third-party materials communicated to ASH Clinical News become its copyrighted property and may be used, reproduced, or otherwise exploited by ASH Clinical News. 5 Focus on Myeloid Malignancies Is Chemoimmunotherapy for Upfront CLL on Life Support? 8 Extinguishing Smoldering Myeloma? 10 Study Finds No Benefit With Post- Induction Treatment Intensification in Children With ALL 33 MEETING NEWS Updates in lymphoid and plasma cell malignancies from the 2019 ASH Annual Meeting 22 All correspondence for the American Society of Hematology should be sent to: American Society of Hematology, 2021 L Street NW, Suite 900, Washington DC 20036. Neither the American Society of Hematology nor the publisher is responsible for statements made by any editor or contributor. Statements, editorials, or opinions expressed in ASH Clinical News magazine do not necessarily represent official policy of the Amer- ican Society of Hematology unless so stated. No responsibility is assumed by the American Society of Hematology or the Publisher for any injury or damage to persons or property as a matter of product liability, negligence or otherwise or from any use or operation of any methods, products, instructions or ideas contained in the material herein.  Although all advertising material published in ASH Clinical News magazine is expected to conform to ethical (medical) stan- dards, inclusion in this publication does not constitute a guarantee or endorsement by the American Society of Hematology or the Publisher of the quality or value of such product or of the claim made of it by its manufacturer. About the American Society of Hematology The American Society of Hematology (ASH) is the world’s largest professional society concerned with the causes and treatments of blood disorders. The mission of the Society is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. March 2020 5